Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment

J Infect Dis. 2000 Jun;181(6):2033-6. doi: 10.1086/315529. Epub 2000 May 31.

Abstract

In order to assess the relationship between human immunodeficiency virus (HIV) RNA, hepatitis C virus (HCV) RNA, CD4, CD8, and liver enzymes during combination antiretroviral therapy, these parameters were measured in 12 HIV-HCV-coinfected patients (who were naive for antiretrovirals) on the day before and 3, 7, 14, 28, 56, and 84 days after initiating the following treatments: stavudine and lamivudine in all patients, indinavir in 6 patients, and nevirapine in 6 patients. HIV RNA declined rapidly, CD4 cells increased slowly, and CD8 cells and liver enzymes were stable. HCV RNA showed a transient significant increase at days 14 and 21 (7.33+/-0.16 [mean +/- SE] and 7.29+/-0.2 log copies/mL vs. 7+/-0.2 log copies/mL at baseline; P<.05). These changes were similar in both treatment groups. A 2-fold alanine aminotransferase increase was observed in 4 of 12 patients; 4 of 4 patients showed increased HCV RNA. The relationship between HCV RNA increase and HIV RNA decrease indicates virus-virus interference. An HCV RNA increase may cause significant liver damage only in a minority of patients.

MeSH terms

  • Adult
  • Alanine Transaminase / blood
  • Anti-HIV Agents / administration & dosage*
  • Drug Therapy, Combination
  • HIV / isolation & purification*
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • Hepacivirus / isolation & purification*
  • Hepatitis C / virology*
  • Humans
  • Liver / physiopathology*
  • Male
  • Pilot Projects
  • RNA, Viral / analysis
  • Virus Replication*

Substances

  • Anti-HIV Agents
  • RNA, Viral
  • Alanine Transaminase